Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2011

View Archived Issues

Merck KGaA presents novel PDK1 inhibitors with potential to treat cancer

Innovative oral MS therapy advances to phase IIa

Summit identifies new approach to treat Alzheimer's disease

Clinical studies evaluate lersivirine versus efavirenz in HIV and its effect on methadone PK

New androgen receptor antagonists reported

S*BIO discloses novel mTOR inhibitors

Novel histamine H4 receptor antagonists prepared by Palau Pharma

Pfizer divulges new MPGES-1 inhibitors for pain

Japanese company patents new angiotensin AT receptor antagonists/PPAR-gamma agonists

D-Pharm clear to continue phase III DP-b99 study

Phase II Aimspro trial for bladder dysfunction in MS advances

Aeterna Zentaris reports nonclinical milestone for oral prostate cancer vaccine

Millennium files sNDA to add survival data to Velcade MM label in U.S.

Pfizer's new opioid NOP receptor antagonists show preclinical potential to treat AD

Potent serotonin 5-HT4 receptor agonist described by Suven

NanoCarrier and Orient Europharma commence phase II study of Nanoplatin

Cellceutix cleared to conduct phase I trial of anticancer drug

Regulus Therapeutics and GSK alliance identifies third microRNA target

EMA accepts Santhera Pharmaceuticals' idebenone MAA for review

First-in-human trial assesses effects of GSK-1034702 on cognitive function

Merck & Co. and Simcere sign agreement to establish joint venture in China

FDA issues safety warning regarding use of Multaq in patients with permanent AF

Bristol-Myers Squibb to acquire Amira Pharmaceuticals

Manhattan Pharmaceuticals and FDA reach agreement on SPA for phase III AST-726 trial

Apricus files MAA in Switzerland for Vitaros

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...